Your browser doesn't support javascript.
loading
Risk Model Development and Validation in Clinical Oncology: Lessons Learned.
Lyman, Gary H; Msaouel, Pavlos; Kuderer, Nicole M.
Afiliação
  • Lyman GH; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kuderer NM; Advanced Cancer Research Group, Kirkland, WA, USA.
Cancer Invest ; 41(1): 1-11, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36254812
ABSTRACT
Reliable risk models can greatly facilitate patient-centered inferences and decisions. Herein we summarize key considerations related to risk modeling in clinical oncology. Often overlooked challenges include data quality, missing data, effective sample size estimation, and selecting the variables to be included in the risk model. The stability and quality of the model should be carefully interrogated with particular emphasis on rigorous internal validation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nomogramas / Oncologia Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Invest Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nomogramas / Oncologia Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Invest Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos